Epigenomics AG banner

Epigenomics AG
F:ECX

Watchlist Manager
Epigenomics AG Logo
Epigenomics AG
F:ECX
Watchlist
Price: 0.91 EUR -8.08% Market Closed
Market Cap: €1m

Wall St Price Targets

ECX Price Targets Summary
Epigenomics AG

There are no price targets for ECX.
Lowest Forecast
Price Target
Not Available
Average Forecast
Price Target
Not Available
Highest Forecast
Price Target
Not Available
Epigenomics AG Competitors:
Price Targets
FBIZ
First Business Financial Services Inc
10% Upside
ULTA
Ulta Beauty Inc
28% Upside
APA
APA Corp (US)
2% Upside
RCR
RL Commercial REIT Inc
16% Upside

Revenue
Forecast

-92% / Year
Past Growth
72% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
-92% / Year
Past Growth
72% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 1 year, the compound annual growth rate for Revenue has been -92%. The projected CAGR for the next 4 years is 72%.

Gross Profit
Forecast

-94% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
-94% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Gross Profit Forecast
is not available for Epigenomics AG

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Pre-Tax Income Forecast
is not available for Epigenomics AG

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is ECX's stock price target?
Not Available

ECX does not have any price targets made by Wall Street professionals.

What is the Revenue forecast for Epigenomics AG?
Projected CAGR
72%

Over the last 1 year, the compound annual growth rate for Revenue has been -92%. The projected CAGR for the next 4 years is 72%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett